<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xml:base="http://www.fiercebioresearcher.com" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
 <title>George Daly</title>
 <link>http://www.fiercebioresearcher.com/tags/george-daly</link>
 <description></description>
 <language>en</language>
<item>
 <title>Stem cell revolutionaries take on big challenges</title>
 <link>http://www.fiercebioresearcher.com/story/stem-cell-revolutionaries-take-big-challenges/2008-06-03?utm_medium=rss&amp;utm_source=rss&amp;cmp-id=OTC-RSS-FBR0</link>
 <description>&lt;p&gt;OncoMed&#039;s Michael Clarke, George Q. Daly at the Harvard Stem Cell Institute, Sir Martin Evans from Cardiff University and Rene Hen from BrainCells/Columbia University are among&amp;nbsp;12 stem cell luminaries highlighted by &lt;em&gt;Forbes&lt;/em&gt;. Collectively they are exploring ways that stem cells can revolutionize the treatment of spinal cord injuries, influence drug toxicity, treat deadly ailments like Tay-Sachs disease or cure type 1 diabetes. And &lt;em&gt;Forbes&lt;/em&gt; highlights new work demonstrating how stem cells can be used to test the safety of experimental therapies--a major advance in a world in which nine out of every 10 new drugs either don&#039;t work or are too toxic.&lt;/p&gt;
&lt;p&gt;&quot;It&#039;s hard to predict the future,&quot; says James Thomson of Cellular Dynamics, &quot;but my guess is that 20 years from now if you look backwards, 90 percent of the value of these cells will be in things that don&#039;t make the front page.&quot;&lt;/p&gt;
&lt;p&gt;- read the &lt;a href=&quot;http://www.forbes.com/home/forbes/2008/0616/088.html&quot;&gt;report&lt;/a&gt; from &lt;em&gt;Forbes&lt;br /&gt;&lt;/em&gt;- click on the &lt;a href=&quot;http://www.forbes.com/home_asia/2008/05/28/stem-cells-biz-healthcare-cx_mh_0528medtech_revolutionaries_slide.html&quot;&gt;link&lt;/a&gt; for the science tour&lt;br /&gt;- read the full Thomson &lt;a href=&quot;http://www.forbes.com/business/2008/05/28/stem-cells-biz-healthcare-cx_mh_0528medtech_thompson.html&quot;&gt;interview&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Related Articles:&lt;br /&gt;&lt;/strong&gt;&lt;a title=&quot;In research, stem cells make another breakthrough&quot; href=&quot;http://www.fiercebiotech.com/story/research-stem-cells-make-another-breakthrough/2007-12-21&quot;&gt;In research, stem cells make another breakthrough&lt;/a&gt;&lt;br /&gt;&lt;a title=&quot;More jaw-dropping scientific advances lay ahead&quot; href=&quot;http://www.fiercebiotech.com/story/more-jaw-dropping-scientific-advances-lay-ahead/2008-01-02&quot;&gt;More jaw-dropping scientific advances lay ahead&lt;/a&gt;&lt;br /&gt;&lt;a href=&quot;http://www.fiercebiotech.com/story/gsk-offers-1-4b-license-oncomed-therapies/2007-12-10&quot;&gt;GSK offers $1.4B to license OncoMed therapies&lt;/a&gt;&lt;/p&gt;</description>
 <comments>http://www.fiercebioresearcher.com/story/stem-cell-revolutionaries-take-big-challenges/2008-06-03#comments</comments>
 <category domain="http://www.fiercebioresearcher.com/tags/braincells">BrainCells</category>
 <category domain="http://www.fiercebioresearcher.com/tags/george-daly">George Daly</category>
 <category domain="http://www.fiercebioresearcher.com/tags/michael-clarke">Michael Clarke</category>
 <category domain="http://www.fiercebioresearcher.com/tags/oncomed">OncoMed</category>
 <category domain="http://www.fiercebioresearcher.com/tags/rene-hen">Rene Hen</category>
 <category domain="http://www.fiercebioresearcher.com/tags/sir-martin-evans">Sir Martin Evans</category>
 <category domain="http://www.fiercebioresearcher.com/tags/stem-cell">Stem Cells</category>
 <category domain="http://www.fiercebioresearcher.com/tags/type-1-diabetes">type I diabetes</category>
 <pubDate>Tue, 03 Jun 2008 08:47:45 -0400</pubDate>
 <dc:creator>John Carroll</dc:creator>
 <guid isPermaLink="false">7891 at http://www.fiercebioresearcher.com</guid>
</item>
</channel>
</rss>
